Results for: ImmPACT Bio

Lyell Immunopharma Inc. (LYEL) has acquired ImmPACT Bio USA Inc., a clinical-stage biotechnology company, for $30 million in cash and 37.5 million Lyell shares. This acquisition brings IMPT-314, a CAR T-cell therapy, to Lyell’s pipeline, but analysts are concerned about the complexities and potential distractions it introduces. Lyell is also discontinuing several programs, including LYL797 and LYL845, to focus on its most differentiated CAR T-cell therapies and the upcoming Phase 1 clinical trial of LYL119. Despite the strategic shift, analysts remain cautious about Lyell’s future due to increased competition and the uncertainty surrounding IMPT-314’s clinical benefits.

Lyell Immunopharma Inc. (LYEL) has acquired ImmPACT Bio USA Inc., a clinical-stage biotechnology company, for $30 million in cash and 37.5 million Lyell shares. This acquisition brings IMPT-314, a CAR T-cell therapy, to Lyell’s pipeline, but analysts are concerned about the complexities and potential distractions it introduces. Lyell is also discontinuing several programs, including LYL797 and LYL845, to focus on its most differentiated CAR T-cell therapies and the upcoming Phase 1 clinical trial of LYL119. Despite the strategic shift, analysts remain cautious about Lyell’s future due to increased competition and the uncertainty surrounding IMPT-314’s clinical benefits.